Cyclin-dependent kinase modulators and cancer therapy

BioDrugs

Volumn 26, Issue 6, 2012, Pages 377-391

  Gallorini, Marialucia ^a   Cataldi, Amelia ^a   Di Giacomo, Viviana ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Alvocidib; Cancer; Cell cycle modulators; Cyclin dependent kinase inhibitors; P 276; Seliciclib; SNS 032

Indexed keywords

ANTINEOPLASTIC AGENT; CLADRIBINE; COLESTYRAMINE; CYCLIN A; CYCLIN B; CYCLIN D; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; CYCLIN H; CYCLIN T1; CYCLOPHOSPHAMIDE; CYTARABINE; FLAVOPIRIDOL; FLUDARABINE; IRINOTECAN; LOPERAMIDE; MITOXANTRONE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; P 276 00; P 27600; PACLITAXEL; ROSCOVITINE; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOMETRIUM CARCINOMA; ENZYME ACTIVATION; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; IC 50; INFLAMMATION; INTRACELLULAR SIGNALING; LOADING DRUG DOSE; LUNG TOXICITY; METASTATIC MELANOMA; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NEUTROPENIA; PHASE TRANSITION; PRIORITY JOURNAL; REVIEW; TUMOR LYSIS SYNDROME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CLINICAL TRIALS AS TOPIC; CYCLIN-DEPENDENT KINASES; CYCLINS; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 84868139125     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11634060-000000000-00000     Document Type: Review

References (142)

1. Pardee AB. G1 events and regulation of cell proliferation. Science 1989; 246: 603-8
2. Morgan DO. Cell cycle control in normal and neoplastic cells. Curr Opin Genet Dev 1992; 2: 33-7
3. Malumbres M, Barbacid M. To cycle or not to cycle: A decision in cancer. Nat Rev Cancer 2001; 1: 222-31
4. Pines J. The cell cycle kinases. Semin Cancer Biol 1994; 5: 305-13 (Pubitemid 124006801)
5. Obaya AJ, Sedivy JM. Regulation of cyclin-CDK activity in mammalian cells. Cell Mol Life Sci 2002; 59: 126-42 (Pubitemid 34117361)
6. Pines J. Cyclins and their associated cyclin-dependent kinases in the human cell cycle. Biochem Soc Trans 1993; 21: 921-5 (Pubitemid 24011757)
7. Ekholm SV, Reed SI. Regulation of G1 cyclin dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 2000; 12: 676-84
8. Harbour JW, Luo RX, Santi AD, et al. CDK phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999; 98: 859-69 (Pubitemid 29446902)
9. Harbour JW, Dean DC. The Rb/ E2F pathway: Expanding roles and emerging paradigms. Genes Dev 2000; 14: 2393-409
10. Oelgeschlager T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J Cell Physiol 2002; 190: 160-9 (Pubitemid 34027819)
11. Morgan DO. Cyclin- dependent kinases: Engines, clocks and microprocessors. Annu Rev Cell Dev Biol 1997; 13: 261-91
12. Espinoza FH, Farrell A, Erdjument-Bromage H, et al. A cyclin-dependent kinase- activating kinase (CAK) in budding yeast unrelated to vertebrate CAK. Science 1996; 273: 1714-7 (Pubitemid 26317787)
13. Fisher RP, Morgan DO. A novel cyclin associates with Mo 15/ CDK7 to form the CDK- activating kinase. Cell 1994; 78: 713-24 (Pubitemid 24268593)
14. Kaldis P, Sutton A, Solomon MJ. The CDK- activating kinase (CAK) from budding yeast. Cell 1996; 86: 553-64 (Pubitemid 26299487)
15. De Bondt HL, Rosenblatt J, Jankarik J, et al. Crystal structure of cyclindependent kinase 2. Nature 1993; 363: 595-602
16. Russo AA, Tong L, Lee JO, et al. Structural basis for inhibition of the cyclindependent kinase CDK6 by the tumor suppressor p16INK4a. Nature 1998; 395: 237-43 (Pubitemid 28447541)
17. Fisher RP. Secret of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci 2005; 118: 5171-80 (Pubitemid 41819581)
18. Fisher RP, Morgan DO. A novel cyclin associates with MO15/CDK7 to form the CDK-Activating kinase. Cell 1994; 78: 713-24 (Pubitemid 24268593)
19. Serizawa H, Mä kelä TP, Conaway JW, et al. Association of Cdk-Activating kinase subunits with transcription factor TFIIH. Nature 1995; 374: 280-2
20. Shiekhattar R, Mermelstein F, Fisher RP, et al. Cdk-Activating kinase (CAK) complex is a component of human transcription factor IIH. Nature 1995; 374: 283-7
21. Feaver WJ, Gileadi O, Li Y, et al. CTD kinase associated with yeast RNA polymerase II initiation factor b. Cell 1991; 67: 1223-30 (Pubitemid 121001534)
22. Lu H, Zawel L, Fisher L, et al. Human general transcription factor IIH phosphorylates theC-terminal domain ofRNApolymerase II.Nature 1992; 358: 641-5
23. Serizawa H, Conaway RC, Conaway JW.Acarboxyl-terminal-domain kinase associated with RNA polymerase II transcription factor delta from rat liver. Proc Natl Acad Sci U S A 1992; 89: 7476-80
24. Dahmus ME. Reversible phosphorylation of the C-terminal domain of RNA polymerase II. J Biol Chem 1996; 271: 19009-12 (Pubitemid 26271553)
25. Martinez AM, Afshar M, Martin F, et al. Dual phosphorylation of the T-loop in cdk7: Its role in controlling cyclin H binding and CAK activity. EMBO J 1997; 16: 343-54 (Pubitemid 27049391)
26. Garrett S, Barton WA, Knights R, et al. Reciprocal activation by cyclindependent kinases 2 and 7 is directed by substrate specificity determinants outside the T-loop. Mol Cell Biol 2001; 21: 88-99
27. Larochelle S, Pandur J, Fisher RP, et al. Cdk7 is essential for mitosis and for in vivo Cdk-Activating kinase activity. Genes Dev 1998; 12: 370-81 (Pubitemid 28084265)
28. Lolli G, Lowe ED, Brown NR, et al. The crystal structure of human CDK7 and its protein recognition properties. Structure 2004; 12: 2067-79 (Pubitemid 39469404)
29. Wallenfang MR, Seydoux G. cdk-7 is required for mRNA transcription and cell cycle progression in Caenorhabditis elegans embryos. Proc Natl Acad Sci U S A 2002; 99: 5527-32 (Pubitemid 34411582)
30. Umeda M, Shimotohno A, Yamaguchi M. Control of cell division and transcription by cyclin-dependent kinase-Activating kinases in plants. Plant Cell Physiol 2005; 46: 1437-42 (Pubitemid 41436585)
31. Adamczewski JP, Rossignol M, Tassan JP, et al. MAT1, cdk7 and cyclin H form a kinase complex which is UV light-sensitive upon association with TFIIH. EMBO J 1996; 15: 1877-84 (Pubitemid 26119692)
32. Rossignol M, Kolb-Cheynel I, Egly JM. Substrate specificity of the cdkactivating kinase (CAK) is altered upon association with TFIIH. EMBO J 1997; 16: 1628-37 (Pubitemid 27151958)
33. Yankulov KY, Bentley DL. Regulation of CDK7 substrate specificity by MAT1 and TFIIH. EMBO J 1997; 16: 1638-46 (Pubitemid 27151959)
34. Larochelle S, Chen J, Knights R, et al. T-loop phosphorylation stabilizes the CDK7-cyclin H-MAT1 complex in vivo and regulates its CTD kinase activity. EMBO J 2001; 20: 3749-59 (Pubitemid 32691786)
35. Grafia X, De Luca A, Sang N, et al. PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro. Proc Natl Acad Sci U S A 1994; 91: 3834-8 (Pubitemid 24139526)
36. Bagella L, MacLachlan TK, Buono RJ, et al. Cloning of murine Cdk9/ PITALRE and its tissue-specific expression in development. J Cell Physiol 1998; 177: 206-13 (Pubitemid 28452821)
37. Leucci E, De Falco G, Onnis A, et al. The role of the cdk9/cyclin T1 complex in T cell differentiation. J Cell Physiol 2007; 212: 411-5 (Pubitemid 47025630)
38. Romano G, Giordano A. Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases. Cell Cycle 2008; 7: 3664-8
39. Lin X, Taube R, Fujinaga K, et al. P-TEFb containing cyclin K and cdk9 can activate transcription via RNA. J Biol Chem 2002; 277: 16873-8 (Pubitemid 34967712)
40. Price DH. P-TEBb, a cyclin-dependent kinase controlling elongation byRNA polymerase II. Mol Cell Biol 2000; 20: 2629-34 (Pubitemid 30183481)
41. De Falco G, Giordano A. CDK9: From basal transcription to cancer and AIDS. Cancer Biol Ther 2002; 1: 342-7
42. Shore SM, Byers SA, Maury W, et al. Identification of a novel isoform of Cdk9. Gene 2003; 307: 175-82 (Pubitemid 36428874)
43. Shore SM, Byers SA, Dent P, et al. Characterization of Cdk955 and differential regulation of two Cdk9 isoforms. Gene 2005; 350: 51-8
44. De Falco G, Leucci E, Onnis A, et al. Cdk9/cyclin T1 complex: A key player during the activation/differentiation process of normal lymphoid B cells. J Cell Physiol 2008; 215: 276-82 (Pubitemid 351363212)
45. Xiao Y, Hendriks J, Langerak P, et al. CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation. J Immunol 2004; 172: 7431-41
46. Giacinti C, Begella L, Puri PL, et al. Myo D recruits the cdk9/cyclin T2 complex on myogenic-genes regulatory regions. J Cell Physiol 2006; 206: 807-13 (Pubitemid 43191056)
47. Iankova I, Petersen RK, Annicotte JS, et al. Peroxisome proliferatoractivated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis. Mol Endocrinol 2006; 20: 1494-505 (Pubitemid 43967559)
48. Foskett SM, Ghose R, Tang DN, et al. Antiapoptotic function of Cdk9 (TAK/P-TEFb) in U937 promonocytic cells. J Virol 2001; 75: 1220-8 (Pubitemid 32094681)
49. De Falco G, Bellan C, D'Amuri A, et al. Cdk9 regulates neural differentiation and its expression correlates with the differentiation grade of neuroblastoma and PNET tumors. Cancer Biol Ther 2005; 4: 277-81 (Pubitemid 41351286)
50. Napolitano G, Majello B, Licciardo P, et al. Transcriptional activity of P-TEFb kinase in vivo requires C-terminal domain of RNA polymerase II. Gene 2000; 254: 139-45
51. Chen R, Keating MJ, Gandhi V, et al. Transcription inhibition by flavopiridol: Mechanism of chronic lymphocytic leukemia cell death. Blood 2005; 106: 2513-9 (Pubitemid 41510827)
52. Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: Insights into drug design from structure. Science 2004; 303: 1800-5 (Pubitemid 38374863)
53. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-12 (Pubitemid 29297917)
54. Shapiro GI. Cyclin-dependent kinase pathway as targets for cancer treatment. J Clin Oncol 2006; 11: 1770-83 (Pubitemid 46628473)
55. Shapiro GI, Park J, Edwards CD, et al. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res 1995; 55: 6200-9
56. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001; 411: 1017-21 (Pubitemid 32612319)
57. Motokura T, Bloom T, Kim HG, et al. A novel cyclin encoded by a bcl 1-linked candidate oncogene. Nature 1991; 350: 512-5 (Pubitemid 21912266)
58. Williams ME, Swerdlow SH, Meeker TC. Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster. Leukemia 1993; 7: 1437-40 (Pubitemid 23291087)
59. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23: 6333-8 (Pubitemid 46218843)
60. Phillips AC, Vousden KH. E2F-1 induced apoptosis. Apoptosis 2001; 6: 173-82 (Pubitemid 32423726)
61. Vandel I, Kouzarides T. Residues phosphorylated by TFIIH are required for E2F-1 degradation during S-phase. EMBO J 1999; 18: 4280-91 (Pubitemid 29364130)
62. Croxton R, Ma Y, Song L, et al. Direct repression of the Mcl-1 promoter by E2F1. Oncogene 2002; 21: 1359-69 (Pubitemid 34214501)
63. Phillips A, Ernst M, Bates S, et al. E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways. Mol Cell 1999; 4: 771-81
64. Peeper DS, Keblusek P, Helin K, et al. Phosphorylation of a specific cdk site in E2F-1 affects its electrophoretic mobility and promotes pRB-binding in vitro. Oncogene 1995; 10: 39-48
65. Chen YNP, Sharma SK, Ramsey TM, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A 1999; 96: 4325-9 (Pubitemid 29190335)
66. O' Connor DS, Wall NR, Porter ACG, et al.Ap34cdc2 survival checkpoint in cancer. Cancer Cell 2002; 2: 43-54
67. Wall NR, O' Connor DS, Plescia J, et al. Suppression of survivin phosphorylation o Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003; 63: 230-5 (Pubitemid 36070444)
68. Alonso M, Tamasdan C, Miller DC, et al. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Mol Cancer Ther 2003; 2: 139-50
69. Demidenko ZN, Blagosklonny MV. Flavopiridol induces p53 via initial inhibition of Mdm-2 and p21 and, independently of p53, sensitizes apoptosis reluctant cells to tumor necrosis factor. Cancer Res 2004; 64: 3653-60 (Pubitemid 38657945)
70. Perez de Castro I, de Cancer G, Malumbres M. A census of mitotic cancer genes: New insights into tumor cell biology and cancer therapy. Carcinogenesis 2007; 28: 899-912 (Pubitemid 47072171)
71. Vizirianakis IS, Chatzopoulou M, Bonovolias ID, et al. Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: Clinical candidates and perspectives. J Med Chem 2010; 53: 6779-810
72. Bible KC, Kaufmann SH. Flavopiridol: A cytotoxic flavones that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 1995; 56: 4856-61 (Pubitemid 26374418)
73. Carlson BA, Dubay MM, Sausville EA, et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 eCDK4 in human breast carcinoma cells. Cancer Res 1996; 56: 2973-8 (Pubitemid 26200251)
74. Carlson B, Lahusen T, Singh S, et al. Downregulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 1999; 59: 4634-41 (Pubitemid 29428969)
75. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000; 92: 376-87 (Pubitemid 30154819)
76. Kaur G, Stetler-Stevenson M, Sebers S, et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavones L86-8275. J Natl Cancer Inst 1992; 84: 1736-40
77. Joshi KS, Rathos MJ, Joshi RD, et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther 2007; 6: 918-25 (Pubitemid 46554561)
78. Conroy A, Stockett DE, Walker D, et al. SNS-032 is a potent and selective CDK2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol 2009; 64: 723-32
79. De Azevedo Jr WF, Mueller-Dieckmann HJ, Shuelze-Gahmen U, et al. Structural basis for specificity and potency of a flavopirinoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad SciU S A 1996; 93: 2735-40 (Pubitemid 26116234)
80. Wright J, Blatner GL, Cheson BD. Clinical trials referral resource: Clinical trials of flavopiridol. Oncology 1998; 12: 1018-24
81. Parker B, Nieves-Neira W, Taimi M, et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998; 91: 458-65 (Pubitemid 28053367)
82. Konig A, Schwartz GK, Mohammed RM, et al. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997; 90: 4307-12 (Pubitemid 27508436)
83. Senderowicz AM. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia 2001; 15: 1-9 (Pubitemid 32124064)
84. Lahusen J, Loaiza-Perez A, Sausville EA, et al. Flavopiridol-induced apoptosis is associated with p38 and MEK activation and is prevented by caspase and MAPK inhibitors. Proceedings of the Twentieth Annual Meeting of the American Association of Cancer Research; 2000 Apr 1-5; San Francisco (CA
85. Senderowicz AM, Headlee D, Stinson SF, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasm. J Clin Oncol 1998; 16: 2986-99 (Pubitemid 28417418)
86. Thomas J, Cleary J, Tutsch K, et al. Phase I clinical and pharmacokinetic trial of flavopiridol. Proceedings of the eighty-eightieth Annual Meeting of the American Association of Cancer Research; 1997 Apr 12-16; San Diego (CA
87. Lin TS, Ruppert AS, Johnson AJ, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009; 27: 6012-8
88. Burdette-Radoux S, Tozer RG, Lohmann RC, et al. Phase II trial of flavopiridol, a cyclin-dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 2004; 22: 315-22 (Pubitemid 39012571)
89. Grendys Jr EC, Blessing JA, Burger R, et al. A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: A Gynecologic Oncology group study. Gynecol Oncol 2005; 98: 249-53 (Pubitemid 41019113)
90. Brusselbach S, Nettelbeck DM, Sedlacek HH, et al. Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells. Int J Cancer 1998; 77: 146-52 (Pubitemid 28308564)
91. Kerr JS, Wexler RS, Mousa SA, et al. Novel small molecule alpha v integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors. Anticancer Res 1999; 19: 959-68 (Pubitemid 29257522)
92. Melillo G, Sausville EA, Cloud K, et al. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelian growth factor expression in human monocytes. Cancer Res 1999; 21: 5433-7 (Pubitemid 29526451)
93. Schwartz GK, O'Reilly E, Ilson D, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002; 20: 2157-70 (Pubitemid 34408808)
94. Shah MA, Kortmansky J, Motwani M, et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 2005; 11: 3836-45 (Pubitemid 40685604)
95. Karp JE, Passaniti A, Gojo I, et al. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-Arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res 2005; 11: 8403-12 (Pubitemid 41746954)
96. Karp JE, Smith BD, Levis MJ, et al. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: A phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res 2007; 13: 4467-73 (Pubitemid 47219715)
97. Karp JE, Smith BD, Resar LS, et al. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 2011; 117: 3302-10
98. Dispenzieri A, Gertz MA, Lacy MQ, et al. Flavopiridol in patients with relapsed or refractory multiple myeloma: A phase 2 trial with clinical and pharmacodynamic end-points. Haematologica 2006; 91: 390-3
99. Bible KC, Bible RHJ, Kottke TJ, et al. Flavopiridol binds to duplex DNA. Cancer Res 2000; 60: 2419-28 (Pubitemid 30262432)
100. Price DH. P-TEFb, a cyclin-dependent kinase controlling elongation byRNA polymerase II. Mol Cell Biol 2000; 20: 2629-34 (Pubitemid 30183481)
101. Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001; 276: 31793-9
102. Wittmann S, Bali P, Donapaty S, et al. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res 2003; 63: 93-9 (Pubitemid 36070425)
103. de Azevedo WFJ, Canduri F, da Silveira NJ. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem Biophys Res Commun 2002; 293: 566-71 (Pubitemid 34694246)
104. Manohar SM, Rathos MJ, Sonawane V, et al. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of CDK9-T1 andRNApolymerase II-dependent transcription. Leuk Res 2011; 35: 821-30
105. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma cells. Blood 2002; 100: 194-9
106. Tong WG, Chen R, Plunkett W, et al. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7 and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol 2010; 18: 3015-22
107. Chen R, Wierda WG, Chubb S, et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 2009; 113: 4637-45
108. Heath EI, Bible K, Martell RE, et al. A phase I study of SNS-032 (formely BMS-387032), a potent inhibitor of cyclin-dependent kinase 2, 7 and 9 administrated as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 2008; 26: 59-65
109. Chen R, Chubb S, Cheng T, et al. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res 2010; 70: 6587-97
110. Boquoi A, Chen T, Enders GH. Chemoprevention of mouse intestinal tumorigenesis by the CDK inhibitor SNS-032. Cancer Prev Res (Phila) 2009; 9: 800-6
111. Tang L, Li MH, Cao P, et al. Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. J Biol Chem 2005; 280: 31220-9 (Pubitemid 41291859)
112. De Azevedo WF, Leclerc S, Mejier L, et al. Inhibition of cyclin-dependent kinases by purine analogues. Crystal structure of human Cdc2 complexed with roscovitine. Eur J Biochem 1997; 243: 518-26 (Pubitemid 27060442)
113. Havlicek L, Hanus J, Vesely J, et al. Cytokinin-derived cyclin-dependent kinase inhibitors: Synthesis and cdc2 inhibitory activity of olomucine and related compounds. J Med Chem 1997; 40: 408-12 (Pubitemid 27080019)
114. Bach S, Knockaert M, Reinhardt J, et al. Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 2005; 280: 31208-19 (Pubitemid 41291858)
115. Fabian MA, Biggs 3rd WH, Treiber DH, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23: 329-36 (Pubitemid 41094421)
116. Whittacker SR, Te Poele RH, Chan F, et al. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis. Cell Cycle 2007; 6: 3114-31
117. Wesierska-Gadek J, Krystof V. Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases. Future reality or utopia? Ann N Y Acad Sci 2009; 1171: 228-41
118. Kim EH, Kim SU, Shin DY, et al. Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 2004; 23: 446-56 (Pubitemid 38174999)
119. Lacrima K, Valentini A, Lambertini C, et al. In vitro activity of cyclindependent kinase CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol 2005; 16: 1169-76 (Pubitemid 41418321)
120. Raje N, Kumar S, Hideshima T, et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via downregulation of Mcl-1 in multiple myeloma. Blood 2005; 106: 1042-7 (Pubitemid 41076452)
121. David-Pfeuty T. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells. Oncogene 1999; 18: 7409-22 (Pubitemid 30035042)
122. Wojciechowski J, Horky M, Guerguieva M, et al. Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induce apoptosis of human MCF-7 breast cancer cells. Int J Cancer 2003; 106: 486-95 (Pubitemid 36969788)
123. Mohapatra S, Coppola D, Riker AL, et al. Roscovitine inhibits differentiation and invasion in a three-dimensional skin reconstruction model of metastatic melanoma. Mol Cancer Res 2007; 5: 145-51 (Pubitemid 46423995)
124. Teodoro JG, Evans SK, Green MR. Inhibition of tumor angiogenesis by p53: A new role for the guardian of the genome. J Mol Med 2007; 85: 1175-86 (Pubitemid 47622219)
125. Dey A, Wong ET, Cheok CF, et al. R-Roscovitine simultaneously targets both the p53 and NF-kappa B pathways and causes potentiation of apoptosis: Implications in cancer therapy. Cell Death Differ 2008; 15: 263-73
126. Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997; 243: 527-36 (Pubitemid 27060443)
127. McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-Roscovitine). Int J Cancer 2002; 102: 463-8 (Pubitemid 35315999)
128. Lacrima K, Lambertini C, Taborelli M, et al. In vitro activity of cyclindependent kinase inhibitor CYC202 (Seliciclib, R-Roscovitine) in mantle cell lymphoma. Ann Oncol 2005; 16: 1169-76 (Pubitemid 41418321)
129. Mohapatra S, Chu B, Zhao X, et al. Accumulation of p53 and reduction in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res 2005; 65: 7717-23 (Pubitemid 41297246)
130. Rogalinska M, Blonski JZ, Komina O, et al. R-Roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspasedependent apoptosis. J Cell Biochem 2010; 109: 217-35
131. Raynaud FI, Whittaker SR, Fischer PM, et al. In vitro and in vivo pharmacokinetic -pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 2005; 11: 4875-87
132. Ljungman M, Paulsen MT. The cyclin-dependent kinase inhibitors roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol Pharmacol 2001; 60: 785-9 (Pubitemid 32900261)
133. Benson C, White J, De Bono J, et al. A phase I trial of the selective oral cyclindependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administrated twice daily for 7 days every 21 days. Br J Cancer 2007; 96: 29-37 (Pubitemid 46094635)
134. Le Tourneau C, Faivre S, Laurence V, et al. Phase I evaluation of seliciclib (Rroscovitine), a novel oral cyclin-dependent kinase inhibitor, with advances malignancies. Eur J Cancer 2010; 46: 3243-50
135. Maier A, Kelter G, Gianella-Borradori A. Antitumor activity of CYC202, a cyclin-dependent inhibitor, in human tumor xenografts in vitro [abstract]. Proc Am Assoc Cancer Res 2003; 44: 3119
136. Hassan M, Sallam H, Hassan Z. The role of pharmacokinetics and pharmacodynamics in early drug development with reference to the cyclindependent kinase (Cdk) inhibitor - Roscovitine. Sultan Qaboos Univ Med J 2011; 11: 165-78
137. Canellos GP. The treatment of chronic granulocytic leukemia. Clin Haematol 1977; 6: 113-28
138. Biedler JL. Drug resistance: Genotype versus phenotype. Cancer Res 1994; 54: 666-78
139. Rowley PT. Chromosome translocations: Dangerous liaisons revisited. Nat Rev Cancer 2001; 1: 245-50
140. Rodrigues AS, Dinis J, Gromicho M, et al. Genomics and cancer drug resistance. Curr Pharm Biotechnol 2012; 13: 651-73
141. Arguello F, Alexander M, Sterry J, et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression and has potent antitumor activity in vivo against human and leukemia xenografts. Blood 1998; 91: 2482-90 (Pubitemid 28155524)
142. Patel V, Senderowicz AM, Pinto D, et al. Flavopiridol, a novel cyclindependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 1998; 102: 1674-81 (Pubitemid 28516252)